File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/rheumatology/keac509
- Scopus: eid_2-s2.0-85152156931
- PMID: 36066415
- WOS: WOS:000859211900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Title | Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes |
---|---|
Authors | |
Keywords | anti-diabetic drugs cohort study crystalline arthropathy diabetes mellitus DPP4 gout metabolic syndrome mortality retrospective study SGLT2 |
Issue Date | 2023 |
Citation | Rheumatology (United Kingdom), 2023, v. 62, n. 4, p. 1501-1510 How to Cite? |
Abstract | Objectives: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. Methods: This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. Results: This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21–71.95, 53.74% males; SGLT2I group: n ¼ 16 144; DPP4I group: n ¼ 27 057] with a median follow-up of 5.59 years (IQR: 5.27–5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. Conclusions: SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use. |
Persistent Identifier | http://hdl.handle.net/10722/330300 |
ISSN | 2023 Impact Factor: 4.7 2023 SCImago Journal Rankings: 1.721 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, Jiandong | - |
dc.contributor.author | Liu, Xuejin | - |
dc.contributor.author | Chou, Oscar Hou In | - |
dc.contributor.author | Li, Lifang | - |
dc.contributor.author | Lee, Sharen | - |
dc.contributor.author | Wong, Wing Tak | - |
dc.contributor.author | Zhang, Qingpeng | - |
dc.contributor.author | Chang, Carlin | - |
dc.contributor.author | Liu, Tong | - |
dc.contributor.author | Tse, Gary | - |
dc.contributor.author | Jing, Fengshi | - |
dc.contributor.author | Cheung, Bernard Man Yung | - |
dc.date.accessioned | 2023-09-05T12:09:22Z | - |
dc.date.available | 2023-09-05T12:09:22Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Rheumatology (United Kingdom), 2023, v. 62, n. 4, p. 1501-1510 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | http://hdl.handle.net/10722/330300 | - |
dc.description.abstract | Objectives: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. Methods: This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. Results: This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21–71.95, 53.74% males; SGLT2I group: n ¼ 16 144; DPP4I group: n ¼ 27 057] with a median follow-up of 5.59 years (IQR: 5.27–5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. Conclusions: SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use. | - |
dc.language | eng | - |
dc.relation.ispartof | Rheumatology (United Kingdom) | - |
dc.subject | anti-diabetic drugs | - |
dc.subject | cohort study | - |
dc.subject | crystalline arthropathy | - |
dc.subject | diabetes mellitus | - |
dc.subject | DPP4 | - |
dc.subject | gout | - |
dc.subject | metabolic syndrome | - |
dc.subject | mortality | - |
dc.subject | retrospective study | - |
dc.subject | SGLT2 | - |
dc.title | Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1093/rheumatology/keac509 | - |
dc.identifier.pmid | 36066415 | - |
dc.identifier.scopus | eid_2-s2.0-85152156931 | - |
dc.identifier.volume | 62 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 1501 | - |
dc.identifier.epage | 1510 | - |
dc.identifier.eissn | 1462-0332 | - |
dc.identifier.isi | WOS:000859211900001 | - |